感染

订阅

MedSci主页 / 所有栏目 / 感染

EMA推荐两药治疗多重耐药结核菌感染

2013-11-26 MedSci MedSci原创

EMA结核
关注

　　2013年11月22日，欧洲药品管理局（EMA）人用药委员会（CHMP）推荐，授权Deltyba (delamanid)和对氨水杨酸（para-aminosalicylic acid）与其他抗多重耐药结核药物一起用于治疗结核。 　　CHMP推荐delamanid用于治疗肺部感染多重耐药结核菌的成人患者，数据显示，接受delamanid治疗的患者获益超过其风

　　2013年11月22日，欧洲药品管理局（EMA）人用药委员会（CHMP）推荐，授权Deltyba (delamanid)和对氨水杨酸（para-aminosalicylic acid）与其他抗多重耐药结核药物一起用于治疗结核。

　　CHMP推荐delamanid用于治疗肺部感染多重耐药结核菌的成人患者，数据显示，接受delamanid治疗的患者获益超过其风险但尚不广泛， 因此CHMP要求还应进行长期有效性的附加研究。CHMP推荐对氨水杨酸用于治疗感染多重耐药结核菌的成人患者和儿科患者。

　　 相关阅读：NEJM：Delamanid可增强耐药结核的疗效

　　 英文链接：European Medicines Agency recommends two new treatment options for tuberculosis

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1670513, encodeId=e34616e051382, content=<a href='/topic/show?id=8445434936c' target=_blank style='color:#2F92EE;'>#多重耐药结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43493, encryptionId=8445434936c, topicName=多重耐药结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e30626711247, createdName=zhang92569, createdTime=Sat Apr 26 23:58:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253894, encodeId=e846125389451, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317209, encodeId=4967131e209d3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522623, encodeId=496e152262371, content=<a href='/topic/show?id=e4084348856' target=_blank style='color:#2F92EE;'>#多重耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43488, encryptionId=e4084348856, topicName=多重耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=476711462137, createdName=gao_jian4221, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=)]
    2014-04-26 zhang92569

    #多重耐药结核#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1670513, encodeId=e34616e051382, content=<a href='/topic/show?id=8445434936c' target=_blank style='color:#2F92EE;'>#多重耐药结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43493, encryptionId=8445434936c, topicName=多重耐药结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e30626711247, createdName=zhang92569, createdTime=Sat Apr 26 23:58:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253894, encodeId=e846125389451, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317209, encodeId=4967131e209d3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522623, encodeId=496e152262371, content=<a href='/topic/show?id=e4084348856' target=_blank style='color:#2F92EE;'>#多重耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43488, encryptionId=e4084348856, topicName=多重耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=476711462137, createdName=gao_jian4221, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=)]
    2013-11-28 huhuaidong387

    #结核#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1670513, encodeId=e34616e051382, content=<a href='/topic/show?id=8445434936c' target=_blank style='color:#2F92EE;'>#多重耐药结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43493, encryptionId=8445434936c, topicName=多重耐药结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e30626711247, createdName=zhang92569, createdTime=Sat Apr 26 23:58:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253894, encodeId=e846125389451, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317209, encodeId=4967131e209d3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522623, encodeId=496e152262371, content=<a href='/topic/show?id=e4084348856' target=_blank style='color:#2F92EE;'>#多重耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43488, encryptionId=e4084348856, topicName=多重耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=476711462137, createdName=gao_jian4221, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=)]
    2013-11-28 fengyi812

    #EMA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1670513, encodeId=e34616e051382, content=<a href='/topic/show?id=8445434936c' target=_blank style='color:#2F92EE;'>#多重耐药结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43493, encryptionId=8445434936c, topicName=多重耐药结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e30626711247, createdName=zhang92569, createdTime=Sat Apr 26 23:58:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253894, encodeId=e846125389451, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317209, encodeId=4967131e209d3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522623, encodeId=496e152262371, content=<a href='/topic/show?id=e4084348856' target=_blank style='color:#2F92EE;'>#多重耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43488, encryptionId=e4084348856, topicName=多重耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=476711462137, createdName=gao_jian4221, createdTime=Thu Nov 28 13:58:00 CST 2013, time=2013-11-28, status=1, ipAttribution=)]
    2013-11-28 gao_jian4221

    #多重耐药#

    0

相关资讯

EMA建议批准洛沙平用于治疗躁动

       欧洲药物管理局（EMA）的一个顾问组建议批准洛沙平（Adasuve，英国Alexa有限公司）用于双相障碍或精神分裂症成年患者快速控制躁动。        周四，欧洲人用药品委员会宣布正式通过了有关该药的正面意见，并建议授予其上市许可权。        &n

EMA支持阿哌沙班用于房颤/卒中适应症

 在欧洲药品管理局委员会（EMA）对人体用医药产品（CHMP）进行的一个积极的评估后，口服Xa因子抑制剂阿哌沙班（Eliquis，施贵宝/辉瑞）可能很快就会能够用于欧洲的患者以减少非瓣膜房颤（AF）患者卒中或全身性栓塞的风险。 这项决定是基于ARISTOTLE研究和AVERROES试验研究中24000例患者的结果。 ARISTOTLE研究显示，不管患者肾功能如何，阿哌沙班预防房颤患者卒中

EMA：Aegerion高胆固醇血症新药Lojuxta获EMA批准

美国生物制药公司Aegerion制药今天宣布，欧洲药品管理局（EMA）已批准将Lojuxta（lomitapide）硬胶囊作为低脂肪饮食及其他降脂药用产品的一种辅助药物，用于纯合子家族性高胆固醇血症（HoFH）成人患者的治疗。 纯合子家族性高胆固醇血症(HoFH)是一种极罕见的常染色体显性遗传性疾病，发病机制为细胞膜表面的低密度脂蛋白（LDL）受体缺如或异常，导致体内LDL代谢异常，造成血浆

EMA批准3种抗肿瘤药 驳回1种

 对于新研发的抗癌药物而言，2012年7月20日是个好日子，欧洲药品管理局（EMA）当天批准了3种抗癌药物，仅驳回1种。辉瑞公司的Xalkori（克里唑蒂尼），武田制药的Adcetris (brentuximab vedotin)以及杨森公司的达珂（地西他滨）均成功获得批准，而Celgene公司的Istodax （romidepsin）则未能入围。     &

EMA：III期试验成功—Medicines耗资$2.4亿收购ProFibrix

Medicines公司今天公布了生物制剂Fibrocaps的关键性III期临床试验FINISH-3的数据，该项试验在美国和西欧的65个站点开展，涉及719例患者，在4个不同的手术适应症脊柱外科、肝切除、软组织剥离、血管手术中，均达到了所有主要和次要止血疗效终点。 Fibrocaps是荷兰生物技术公司ProFibrix开发的一种生物制剂，这是一种干粉外用配方的纤维蛋白原和凝血酶，开发用于手术过

EMA警告：长期注射或输注含降钙素药物可增加癌症风险

　　7月19日，因可增加癌症风险，欧洲药品管理局（EMA）人用药物委员会（CHMP）建议，将降钙素鼻腔喷雾（用于治疗骨质疏松症）在欧盟撤市。 　　EMA指出，长期注射或输注含降钙素药物可增加癌症风险。因此，只推荐将其短期用于3种情况：佩吉特（Paget）病（≤3个月）、突发性制动引起的急性骨质丢失（≤4周）和癌症引起的高血钙症（未规定具体疗程）。在此3种情况下使用该药物此前已获欧盟批准。